AMY AGENA: Open Payments
NPI 1114195526 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$922 in 54 payments from 12 companies in 2025. Trend: 2023 $695 · 2024 $491 · 2025 $922
Food & beverage: $922
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $328 |
| Novo Nordisk Inc | 19 | $257 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $83 |
| Boston Scientific Corporation | 1 | $48 |
| AstraZeneca Pharmaceuticals LP | 3 | $43 |
| Janssen Pharmaceuticals, Inc | 2 | $40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $31 |
| Abbott Laboratories | 1 | $24 |
| Biogen, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $18 |
Products named: VRAYLAR, Wegovy, Ozempic, CAPLYTA, QULIPTA, General - Pain Management, UBRELVY, Rybelsus.
Industry payments across NE — which companies pay providers there.
